Microneedling for Burn Hypertrophic Scars
Launched by CENTRE HOSPITALIER DE L'UNIVERSITÉ DE MONTRÉAL (CHUM) · Jun 14, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a treatment called microneedling for people who have developed hypertrophic scars after suffering burns. Hypertrophic scars are raised, red scars that can be painful and itchy, affecting the quality of life for burn survivors. The trial aims to see if microneedling, which uses a special device to create tiny channels in the skin, can improve the appearance and feel of these scars when combined with a cortisone treatment.
To participate in this study, you need to be at least 16 years old and have at least two hypertrophic scars. The trial is open to all genders and races. However, if you have keloid scars, mature scars, certain skin conditions, or other specific health issues, you may not be eligible. If you join the trial, you can expect to receive up to five microneedling treatments followed by cortisone application to help your scars improve. The trial is currently recruiting participants, so if this sounds like it could help you, consider reaching out for more information!
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Any gender or race
- • 16 years of age or older
- • Have at least 2 HSc that meet the clinical criteria for HSc
- • Provide written informed consent.
- Exclusion Criteria:
- • Patients with keloid scars
- • Mature scar site
- • A psychiatric condition or cognitive impairment that interferes with their ability to follow the treatment protocol
- • Dermatological conditions (i.e. psoriasis, eczema, etc.) in the area of the evaluation site
- • An allergy to ultrasound gel
- • On anticoagulant medications
- • Inability to understand English or French.
About Centre Hospitalier De L'université De Montréal (Chum)
The Centre Hospitalier de l'Université de Montréal (CHUM) is a leading academic health institution in Canada, dedicated to advancing patient care through innovative research and clinical excellence. As a prominent sponsor of clinical trials, CHUM is committed to leveraging its multidisciplinary expertise and state-of-the-art facilities to facilitate groundbreaking studies that enhance medical knowledge and improve health outcomes. Collaborating with a network of healthcare professionals and researchers, CHUM fosters a rigorous research environment that prioritizes patient safety, ethical standards, and scientific integrity, positioning itself at the forefront of medical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montréal, , Canada
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials